XML 12 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Feb. 24, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001439725    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-39659    
Entity Registrant Name Biodesix, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-3986492    
Entity Address, Address Line One 919 West Dillon Rd    
Entity Address, City or Town Louisville    
Entity Address, State or Province CO    
Entity Address, Postal Zip Code 80027    
City Area Code 303    
Local Phone Number 417-0500    
Title of 12(b) Security Common Stock, par value $0.001 per share    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Trading Symbol BDSX    
Security Exchange Name NASDAQ    
Entity Well Known Seasoned Issuer No    
Entity Voluntary Filers Yes    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   145,978,410  
Entity Public Float     $ 74.0
Auditor Name KPMG LLP    
Auditor Location Denver, CO    
Auditor Firm ID 185    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Company’s definitive Proxy Statement for its 2024 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.

    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Biodesix, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.